← Back to Clinical Trials
Recruiting NCT07366879

NCT07366879 Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hypertension

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07366879
Status Recruiting
Phase
Sponsor Golden Jubilee National Hospital
Condition Pulmonary Arterial Hypertension
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2026-04-02
Primary Completion 2027-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Home-based, remotely delivered, supervised Exercise programme

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2026-04-02 with a primary completion date of 2027-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn if an exercise programme started shortly after diagnosis improves the fitness and mental wellbeing of patients with pulmonary hypertenion over and above medication alone. It will also learn about whether extra support can help patients keep up with exercise in the long term. The main questions it aims to answer are: * Doe exercise improve how far patients can walk over six minutes * Does exercise improve quality of life scores * Does exercise improve mental health scores * Does extra support after an exercise programme help patients to continue exercising in the long term Researchers will compare the exercise programme to a control group (a group of similar patients who do not receive the exercise programme) to see the effect that exercise has. Participants in the exercise programme group will: * Undergo an exercise programme for 12 weeks, starting around 3 months after their diagnosis * They will undertake the exercise programme at home, remotely supervised by the research team with regular contact * Visit the clinic at the end of the programme for checkups and tests * Keep a diary of their exercise and how they are feeling Participants in the control group will: -Still undergo the exercise programme, but this will happen at a delayed time, starting around 6 months after diagnosis, to allow for a comparison between the two groups. Following completion of the exerise programme: * Half of participants will receive extra support to help them continue to exercise * The other half will not receive any additional support * All patients will be reviewed 1 year following the completion of their exercise programme to monitor their ongoing exercise levels.

Eligibility Criteria

Inclusion Criteria: * Aged 18-years-old and above * Diagnosed with pulmonary hypertension (group I and non-operable group IV) by right heart catheterisation showing: * a baseline mean pulmonary artery pressure \>20mmHg * pulmonary vascular resistance \>2 Wood Units * pulmonary capillary wedge pressure \<15mmHg * Able to provide written informed consent Exclusion Criteria: * Diagnosis with pulmonary hypertension of any other cause * Group II (PH due to left heart disease) * Group III (PH due to hypoxic lung disease) * Operable group IV (PH due to chronic thromboembolic disease amenable to surgical treatment) * Group V (unclear and/or multifactorial elements). * Planned treatment with a research trial medication during the study timeframe * Consenting clinician and/or patient concern regarding the patient's safety in performing a home-based exercise programme * Patients with syncopal episodes felt to be related to pulmonary hypertension at time of exercise intervention initiation. * Severe concurrent medical condition that would prevent participation in study procedures * Life expectancy \<3 months

Contact & Investigator

Central Contact

Jamie Ingram, MBChB

✉ jamie.ingram2@nhs.scot

📞 0044 141-951-5440

Frequently Asked Questions

Who can join the NCT07366879 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Arterial Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07366879 currently recruiting?

Yes, NCT07366879 is actively recruiting participants. Contact the research team at jamie.ingram2@nhs.scot for enrollment information.

Where is the NCT07366879 trial being conducted?

This trial is being conducted at Glasgow, United Kingdom.

Who is sponsoring the NCT07366879 clinical trial?

NCT07366879 is sponsored by Golden Jubilee National Hospital. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology